<DOC>
	<DOCNO>NCT01320176</DOCNO>
	<brief_summary>This study aim evaluate safety reactogenicity two intramuscular injection two different dosage investigational clade B HIV vaccine .</brief_summary>
	<brief_title>Study Evaluate Dosage Safety Two Intramuscular Injections Investigational Clade B HIV Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subjects investigator believe comply requirement protocol ( e.g . completion diary card , return followup visit ) available schedule visit investigational site 2 . Adult male female subject 18 27 year old . 3 . Proven record measles vaccination ( long 5 year ) 4 . Measles antibodies titre &lt; 350 IU/L &gt; 750 IU/L measure previous study `` CEVAC seroMV001 '' . 5 . Healthy subject establish medical history clinical examination enter study . 6 . Confirmed HIV negative base absence antibody p24 . 7 . Negative Hepatitis B surface ( HBs ) antigen , antihepatitis B core ( HBc antibody ) antibody antiHepatitis C Virus ( HCV ) antibody 1 . Participation another clinical study last 6 month subject expose investigational product ( pharmaceutical product placebo device ) concurrent participation another clinical study study period . 2 . Previous inclusion HIV vaccine study . 3 . Receipt vaccination 1 month plan receive vaccination 1 month study vaccination 4 . Receipt tuberculin skin test 1 month plan receive tuberculin test 1 month study vaccination 5 . Receipt allergy treatment antigen injection 1 month plan receive allergy treatment antigen injection 1 month study vaccination 6 . Receipt blood product immunoglobulins within 120 day prior enrolment . 7 . Measles vaccination booster within last 5 year confirm medical history . 8 . Subject pregnant breastfeeding intend become pregnant within 9 month enrol study . 9 . Subject childbearing potential agree use medically acceptable form contraception duration study ( 9 month post first investigational HIV vaccination ) . Medically acceptable form contraception include : Contraceptive Medication , Intrauterine device , Double barrier method ( Condom* Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . * A female condom male condom use together friction two result either product failing . 10 . History significant immunodeficient condition . 11 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior first vaccination 12 . Individuals high risk acquire HIV infection determine risk assessment questionnaire . 13 . Individuals live and/or work severely immunocompromised people , child 15 month old pregnant woman . 14 . Family history immunodeficiency and/or personal history autoimmune disease ( include psoriasis , rheumatoid arthritis , autoimmune thyroid disease ) . 15 . History type I type II diabetes mellitus include case control diet alone . 16 . History ongoing malignancy . 17 . Major congenital defect serious chronic illness time enrolment . 18 . History serious adverse reaction vaccine administration , include anaphylaxis relate symptom , urticaria , respiratory difficulty , angioedema abdominal pain vaccine , history allergic reaction likely exacerbated component vaccine . 19 . Acute chronic , clinically significant , determined investigator , pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . 20 . Individuals whose Body Mass index ( BMI ) less 18.5 great 30 ( i.e . underweight obese ) . 21 . History clinically significant , determined investigator , neurological disorder seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>27 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>